CN107858375A - 非b亚型gag蛋白在慢病毒包装中的应用 - Google Patents

非b亚型gag蛋白在慢病毒包装中的应用 Download PDF

Info

Publication number
CN107858375A
CN107858375A CN201710942647.XA CN201710942647A CN107858375A CN 107858375 A CN107858375 A CN 107858375A CN 201710942647 A CN201710942647 A CN 201710942647A CN 107858375 A CN107858375 A CN 107858375A
Authority
CN
China
Prior art keywords
leu
gly
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710942647.XA
Other languages
English (en)
Chinese (zh)
Inventor
T-L·特兰
P·沙纽
C·伯奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sai Lafukedisi Co
Institut Pasteur
Original Assignee
Sai Lafukedisi Co
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47522726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107858375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sai Lafukedisi Co, Institut Pasteur filed Critical Sai Lafukedisi Co
Publication of CN107858375A publication Critical patent/CN107858375A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201710942647.XA 2011-09-26 2012-09-25 非b亚型gag蛋白在慢病毒包装中的应用 Pending CN107858375A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306222 2011-09-26
EP11306222 2011-09-26
CN201280046712.6A CN104039968B (zh) 2011-09-26 2012-09-25 非b亚型gag蛋白在慢病毒包装中的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280046712.6A Division CN104039968B (zh) 2011-09-26 2012-09-25 非b亚型gag蛋白在慢病毒包装中的应用

Publications (1)

Publication Number Publication Date
CN107858375A true CN107858375A (zh) 2018-03-30

Family

ID=47522726

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710942647.XA Pending CN107858375A (zh) 2011-09-26 2012-09-25 非b亚型gag蛋白在慢病毒包装中的应用
CN201280046712.6A Active CN104039968B (zh) 2011-09-26 2012-09-25 非b亚型gag蛋白在慢病毒包装中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280046712.6A Active CN104039968B (zh) 2011-09-26 2012-09-25 非b亚型gag蛋白在慢病毒包装中的应用

Country Status (14)

Country Link
US (2) US9752160B2 (enExample)
EP (1) EP2761011B1 (enExample)
JP (3) JP6495653B2 (enExample)
KR (1) KR101811736B1 (enExample)
CN (2) CN107858375A (enExample)
AU (1) AU2012313960B2 (enExample)
BR (1) BR112014007027A2 (enExample)
CA (2) CA2959867C (enExample)
DK (1) DK2761011T3 (enExample)
ES (1) ES2683820T3 (enExample)
IL (1) IL231666B (enExample)
SG (1) SG11201400987QA (enExample)
WO (1) WO2013046034A2 (enExample)
ZA (1) ZA201401780B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913854A1 (en) 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
WO2015063706A1 (en) * 2013-10-31 2015-05-07 Theravectys Lentiviral vectors for expression of hiv-1 antigens
EP3009144A1 (en) * 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
US12084674B2 (en) * 2019-10-07 2024-09-10 University Of Utah Research Foundation Methods and compositions for a HIV based delivery system
US20250319173A1 (en) * 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101353667A (zh) * 2008-08-15 2009-01-28 中国人民解放军军事医学科学院微生物流行病研究所 Hiv毒株耐药表型分析细胞模型及其专用假型慢病毒
CN101680003A (zh) * 2007-02-12 2010-03-24 Ark治疗学有限公司 用于将蛋白插入到慢病毒载体中的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646606B1 (fr) * 1989-05-03 1994-06-17 Inst Nat Sante Rech Med Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
EP1610816B1 (en) * 2003-03-28 2013-01-02 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mva virus expressing modified hiv envelope, gag, and pol genes
GB0318704D0 (en) * 2003-08-08 2003-09-10 Sirus Pharmaceuticals Ltd Chimaeric vector system
CA2539021A1 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101680003A (zh) * 2007-02-12 2010-03-24 Ark治疗学有限公司 用于将蛋白插入到慢病毒载体中的方法
CN101353667A (zh) * 2008-08-15 2009-01-28 中国人民解放军军事医学科学院微生物流行病研究所 Hiv毒株耐药表型分析细胞模型及其专用假型慢病毒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEAN DE MAREUIL ET AL.，: "The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain", 《JOURNAL OF VIROLOGY》 *
TOM DULL ET AL.，: "A Third-Generation Lentivirus Vector with a Conditional Packaging System", 《JOURNAL OF VIROLOGY》 *
韩凌霞等: "EIAV 基因转移载体包装盒表达质粒的构建", 《中国预防兽医学报》 *

Also Published As

Publication number Publication date
BR112014007027A2 (pt) 2017-04-11
CA2959867C (en) 2020-04-28
KR101811736B1 (ko) 2017-12-22
JP2017018132A (ja) 2017-01-26
ES2683820T3 (es) 2018-09-28
IL231666B (en) 2018-03-29
WO2013046034A3 (en) 2013-05-30
WO2013046034A2 (en) 2013-04-04
ZA201401780B (en) 2015-09-30
JP6495653B2 (ja) 2019-04-03
JP2014530000A (ja) 2014-11-17
CN104039968A (zh) 2014-09-10
EP2761011A2 (en) 2014-08-06
AU2012313960A1 (en) 2014-04-10
KR20140116053A (ko) 2014-10-01
US9752160B2 (en) 2017-09-05
AU2012313960B2 (en) 2016-05-12
HK1200870A1 (en) 2015-08-14
JP2018183165A (ja) 2018-11-22
CA2849652A1 (en) 2013-04-04
CA2849652C (en) 2017-11-21
NZ622860A (en) 2016-05-27
EP2761011B1 (en) 2018-05-23
CA2959867A1 (en) 2013-04-04
US20170362607A1 (en) 2017-12-21
IL231666A0 (en) 2014-05-28
US20140234908A1 (en) 2014-08-21
CN104039968B (zh) 2018-10-26
SG11201400987QA (en) 2014-07-30
DK2761011T3 (en) 2018-08-27

Similar Documents

Publication Publication Date Title
CA2331599C (en) Replication defective hiv vaccine
CN1913919B (zh) 基于hiv多进化枝的env的hiv疫苗
Hirsch et al. A distinct African lentivirus from Sykes' monkeys
KR101811736B1 (ko) 렌티바이러스 패키징을 위한 비-서브타입 b gag 단백질의 용도
US8076100B2 (en) Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US5554524A (en) More complex type retroviruses having mixed type LTR, and uses thereof
Müller-Trutwin et al. The Evolutionary Rate of Nonpathogenic Simian Immunodeficiency Virus (SIVagm) Is in Agreement with a Rapid and Continuous Replicationin Vivo
Pandya et al. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system
DK2020444T3 (en) DEFECTIVE NON-INTEGRATIVE LENTIVIRAL TRANSMISSION VECTORS FOR VACCINES
ES2329648T3 (es) Clones moleculares con genes mutados gag/pol de vih, gag de vis y env de vis.
Neumann et al. Retroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV (HIV-1) pseudotype vector
HK1200870B (en) Use of non-subtype b gag proteins for lentiviral packaging
Langhammer Neutralisierende Antikörper gegen die transmembranen Hüllproteine von Retroviren
NZ622860B2 (en) Use of non-subtype b gag proteins for lentiviral packaging
Smith Design and immunogenicity of a DNA vaccine against primate lentiviruses
CA2376790A1 (en) Siv-based packaging-defficient vectors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180330